Myopathy secondary to the treatment with inhibitors of HMG-CoA reductase
Fuentes, I.; Aguilera, C.
Medicina Clinica 111(18): 700
1998
ISSN/ISBN: 0025-7753 PMID: 9887435 Document Number: 487634
Document emailed within 1 workday
Related Documents
Hoeg, J.M.; Brewer, H.B. 1987: 3-Hydroxy-3-methylglutaryl--coenzyme a reductase inhibitors in the treatment of hypercholesterolemia JAMA 258(24): 3532-3536Wright, M.; Hill, S.; Slaney, M.A. 1994: The role of aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy Medical Journal of Australia 160(1): 45
Yue, D.K.; Brooks, B. 1993: The role of aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy Medical Journal of Australia 159(2): 76-78
Yamamoto, A. 2001: HMG-CoA reductase inhibitors Nihon Rinsho. Japanese Journal of Clinical Medicine 59(Suppl 3): 578-586
Tomita, N.; Morishita, R.; Ogihara, T. 2002: Pharmacological effects of HMG-CoA reductase inhibitors Nihon Rinsho. Japanese Journal of Clinical Medicine 60(5): 955-961
Davignon, J.; Montigny, M.; Dufour, R. 1992: HMG-CoA reductase inhibitors: a look back and a look ahead Canadian Journal of Cardiology 8(8): 843-864
Milpied-Homsi, B.; Krempf, M.; Gueglio, B.; Raffi, F.; Stalder, J.F. 1999: "Buffalo neck": an unintended secondary effect of treatment with anti-HIV protease inhibitors Annales de Dermatologie et de Venereologie 126(3): 254-256
Erkelens, D.W.; Bravenboer, B. 1990: Aldose reductase inhibitors in diabetic neuropathy Nederlands Tijdschrift Voor Geneeskunde 134(15): 775-776
Gmiński, J.; Wojakowski, W. 1997: Anti-atherosclerotic actions of HMG-CoA reductase inhibitors Przeglad Lekarski 54(11): 782-787
Batzold, F.H. 1981: Approaches to prostatic 5 alpha-reductase inhibitors Progress in Clinical and Biological Research 75b: 269-282
Bowden, K.; Harris, N.V.; Watson, C.A. 1993: Structure-activity relationships of dihydrofolate reductase inhibitors Journal of ChemoTherapy 5(6): 377-388
Klotz, L.H. 2006: Androgen replacement and/or 5 alpha reductase inhibitors in aging men Canadian Journal of Urology 13(Suppl 1): 44-45
Bagi, C.M. 2002: HMG-CoA reductase inhibitors - a review of the recent patent literature Idrugs: the Investigational Drugs Journal 5(3): 266-277
Cecha, J.ós.; Drabek, G.; Błazelonis, A.; Romanowski, W.; Zubelewicz-Szkodzińska, B. 2004: The role of HMG-CoA reductase inhibitors in regulation of the inflammatory processes Wiadomosci Lekarskie 57(5-6): 255-258
Berger, G.M.; Marais, A.D.; Firth, J.C. 1990: New drugs for treating hypercholesterolemia and other hyperlipidaemias--the HMG CoA reductase inhibitors South African Medical Journal 77(2): 57-59
Djavan, B.; McConnell, J. 1996: The effect of 5-alpha-reductase inhibitors on benign prostatic hyperplasia Wiener Medizinische Wochenschrift 146(8): 165-168
Azzouni, F.; Zeitouni, N.; Mohler, J. 2013: Role of 5α-reductase inhibitors in androgen-stimulated skin disorders Journal of Drugs in Dermatology: Jdd 12(2): E30-E35
Hartman, P.G. 1993: Molecular aspects and mechanism of action of dihydrofolate reductase inhibitors Journal of Chemotherapy 5(6): 369-376
Truong, H.; Logan, J.; Turkbey, B.; Siddiqui, M.M.; Rais-Bahrami, S.; Hoang, A.N.; Pusateri, C.; Shuch, B.; Walton-Diaz, A.; Vourganti, S.; Nix, J.; Stamatakis, L.; Harris, C.; Chua, C.; Choyke, P.L.; Wood, B.J.; Pinto, P.A. 2013: MRi characterization of the dynamic effects of 5α-reductase inhibitors on prostate zonal volumes Canadian Journal of Urology 20(6): 7002-7007
Schwartzkopff, W.; Bimmermann, A.; Schleicher, J. 1990: Comparison of the effectiveness of the HMG-CoA-reductase inhibitors pravastatin versus colestyramine in hypercholesteremia Arzneimittel-Forschung 40(12): 1322-1327